The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK ...

Austria’s HeartBeat.bio and biotx.ai have announced a strategic partnership to identify and validate novel therapeutic ...

Swissmedic has introduced a fast-track review process for clinical trial applications, aiming to speed up access to ...

Last week’s announcement of a Life Science Strategy from the European Commission, includes action to address long-standing ...

Indian biosimilars company Biocon Biologics, a subsidiary of Biocon Ltd (BSE: 532520), today announced that the UK’s ...

A Dutch appeals court has ruled that health insurers acted unlawfully in their group tender for three CDK 4/6 inhibitors, ...

Since July 2016, and in line with the Irish Pharmaceutical Healthcare Association (IPHA) Code of Practice for the ...

Japan’s Nxera Pharma is to receive a $4.8 million milestone payment from UK pharma company Centessa Pharmaceuticals as part of the firms’ research collaboration.

A nasal COVID-19 vaccine developed by US biotech CyanVac has produced encouraging results in an early trial, showing potential to offer broader immunity and easier delivery than current injections.